Elekta started FY 23/24 on a healthy note, with Q1 sales and operating profitability beating street expectations for the third consecutive quarter. Top-line growth was driven by healthy contributions from both segments. Notably, margin improvements, backed by healthy momentum in the top line along with lower logistic costs, and the gains from the cost-reduction initiative were a surprise factor. Overall, with a rising global cancer incidence along with Elekta’s focus on underpenetrated markets a ....
